Johnson & Johnson (NYSE:JNJ) shares acquired by Summit Trail Advisors LLC

Vaseline4 weeks ago

0 4 minutes read

Summit Trail Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 30.7% in the second quarter, Holdings Channel reports. The institutional investor owned 45,920 shares of the company’s stock after acquiring an additional 10,789 shares during the quarter. Summit Trail Advisors LLC’s holdings in Johnson & Johnson were worth $6,712,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Meridian Financial Partners LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth $1,626,000. Summit Financial Wealth Advisors LLC boosted its stake in Johnson & Johnson by 26.3% in the first quarter. Summit Financial Wealth Advisors LLC now owns 5,392 shares of the company’s stock worth $853,000 after purchasing an additional 1,122 shares in the last quarter. Gilbert & Cook Inc. raised its position in Johnson & Johnson by 3.3% in the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after acquiring an additional 288 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC boosted its position in shares of Johnson & Johnson by 0.7% in the first quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the company’s stock worth $7,464,000 after buying an additional 325 shares during the last quarter. Finally, Capital Asset Advisory Services LLC boosted its holdings in shares of Johnson & Johnson by 8.8% in the first quarter. Capital Asset Advisory Services LLC now owns 26,539 shares of the company’s stock valued at $4,044,000 after acquiring an additional 2,151 shares during the period. 69.55% of the shares are currently held by hedge funds and other institutional investors.

Analysts on Wall Street are forecasting an increase

JNJ has been the subject of several recent research reports. TD Cowen decreased their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. TD Securities cut their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Morgan Stanley raised their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Finally, Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the company from $160.00 to $150.00 in a report on Tuesday, July 23. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $173.21.

Want more great investment ideas?

Check out our latest research report on JNJ

Insider buying and selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this link. Insiders own 0.16% of the company’s shares.

Johnson & Johnson stock performance

Shares of JNJ stock opened at $164.11 on Friday. The company has a market cap of $394.96 billion, a price-to-earnings ratio of 10.23, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The firm has a fifty day moving average of $161.30 and a 200 day moving average of $154.20. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85, and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue rose 4.3% year-over-year. In the same period last year, the company earned $2.80 per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson announces dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents an annualized dividend of $4.96 and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.